Presented by: Yuriy Kim
Yu.A.Kim

Introduction

The effectiveness of a standard 12-point prostate biopsy is largely dependent on the experience of the specialist. One of the most promising, non-invasive methods of additional imaging in prostate biopsy is histoscanning. Using the True Targeting software allows you to perform a targeted biopsy in real time.

The purpose of the study is to evaluate the effectiveness of performing prostate biopsy under the control of hostoscanning in the day stay unit.

Materials

 From May 2019 to April 2022. In the day stay unit on the basis of the S.I. Spasokukotsky state clinic 2800 patients with suspected prostate cancer underwent transrectal histoscanning prostate biopsy in real-time.

Results

,

The average prostate-specific antigen value was 14,23 ng/ml (varied from 0,5 to 1900 ng/ml). The average age of the patients was 66 years, the average prostate volume was 53,89 cm3. The average time of a transrectal histoscanning prostate biopsy is 17 minutes. The average number of biopsies taken was 16 (of which 4 were targeted). Primary biopsy was performed in 1296 patients (82%), repeated - in 504 patients (18%). The presence of prostate cancer in close relatives was noted in 84 patients (3%). Among them, prostate cancer was detected in 69 patients, which is 82%. Suspicious sites were mainly located in the anterior sections of the prostate, which are usually missed when performing a standard transrectal biopsy. The overall incidence of prostate cancer was 59%, and with a standard biopsy this figure was 17%, while with a hostoscan-targeted biopsy prostate cancer was diagnosed in 6% of cases.

 

Conclusion

The conducted study showed high efficiency of prostate biopsy under histoscanning control in conditions of day stay unit. The use of this method allows to increase the incidence of clinically significant prostate cancer and influence the choice of further treatment tactics.

Funding

No

Lead Authors

Dmitry Pushkar, MD
Academician of RAS, Prof., Head of the Department of Urology, A.I. Evdokimov Moscow State University of Medicine and Dentistry

Co-Authors

Alexander Govorov, MD
Associate Professor at the Department of Urology, A.I. Evdokimov Moscow State University of Medicine and Dentistry

Alexander Vasilyev, PHD
PhD, Teaching Assistant at the Department of Urology, A.I. Evdokimov Moscow State University of Medicine and Dentistry

Anton Sadchenko, PHD
Urologist at the Department of Urology, A.I. Evdokimov Moscow State University of Medicine and Dentistry

Pavel Arutyunyan,
Urologist at the Department of Urology, A.I. Evdokimov Moscow State University of Medicine and Dentistry